

Article: 1615

Topic: EPV27 - e-Poster 27: Psychopharmacology and Pharmacoeconomics

---

## Modelling the Economic Impact of Desvenlafaxine Versus Venlafaxine as a Second Line Therapy of Major Depressive Disorder Patients in Spain

S. Serip<sup>1</sup>, F. Pérez-Alcántara<sup>1</sup>, J. Gascón<sup>2</sup>, M. Blanca-Tamayo<sup>3</sup>, **J. Rejas-Gutiérrez**<sup>4</sup>

<sup>1</sup>Pharmacoeconomics, Oblikue Consulting, Barcelona, Spain ; <sup>2</sup>Department of Psychiatry, Hospital

Universitario Mútua Terrassa, Terrasa, Spain ; <sup>3</sup>Unit of Psychiatry, Badalona Serveis Assistencials S.A.,

Badalona, Spain ; <sup>4</sup>Health Economics and Outcomes Research Department, Pfizer S.L.U., Alcobendas, Spain

---

**Aim:** To model the cost and consequences of desvenlafaxine and venlafaxine in the second-line outpatient treatment of major depressive disorder (MDD) from the payer (National Health System) perspective in Spain.

**Methods:** The model (a Markov simulation) follows a cohort of MDD patients through 1 year after failure of first-line treatment with a Selective-Serotonin-Reuptake-Inhibitor (SSRI) and estimates outcome measures (% in remission and depression-free days) accrued and costs incurred during outpatient treatment of MDD. Selected comparator is venlafaxine because its actual generic price. The model also considers drug treatment switching beyond the second-line of therapy (3<sup>rd</sup> line) or changing to another drugs in 4<sup>th</sup>-line in cases of patient discontinuation or lack of remission according with outcomes from STAR-D trial. Efficacy of drugs was extracted from clinical trial published. The model generates outcomes and cost from the NHS in year 2014.

**Results:** Due to fewer discontinuations, desvenlafaxine was associated with numerically more depression-free days and a higher percentage of patients in remission versus venlafaxine: 1.7 days and 0.5% more in remission. Also, healthcare costs were a little bit lower with desvenlafaxine than with venlafaxine: €1,114 vs. €1,166 (-52€).

**Conclusion:** In patients who have not responded to a first-line SSRI therapy, desvenlafaxine-50mg was clinically similar in effectiveness but a less costly option (about 5% lower) compared with venlafaxine for the second-line treatment of MDD patients from a payer (NHS) perspective in Spain.